INTRODUCTION
• In Europe in 2012, lung cancer was diagnosed in more than 400,000 patients and caused nearly 350,000 deaths. 4, 5 • Patients with unresectable stage III NSCLC typically receive definitive platinum-based chemotherapy given concurrently with radiotherapy (i.e., concurrent chemoradiation).
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Following chemoradiation, median progression-free survival is an estimated 8 months, and 5-year survival is 15%. 7, 8 • Poor prognosis associated with unresectable stage III NSCLC and the limited effectiveness of standard care indicate a continued need for effective treatment options.
Research on real-world treatment, outcomes, and health care resource burden associated with unresectable stage III NSCLC may provide needed data for assessing unmet treatment needs and current information for evaluating the impact of future novel therapies for treating NSCLC.
CONCLUSIONS
• In this study, patients treated with concurrent chemoradiation generally initiated treatment according to guidelines.
• In the UK and Germany, most patients completed definitive chemoradiation therapy as planned. A substantial proportion of patients receive additional treatment after the index chemoradiation treatment and stopped due to disease progression, particularly in Spain.
• PD-L1 testing was uncommon at the index date. Given the high level of expression in patients that were tested, testing for PD-L1 expression in earlier stages may assist in identifying patients who may benefit from novel immuno-oncology therapies. 
RESULTS

METHODS
• We conducted a retrospective medical record review of patients treated with at least two cycles of concurrent chemoradiation for unresectable, locally advanced, stage III NSCLC in the UK, Germany, and Spain.
• A convenience sample of oncologists selected a quasi-random sample of patients from their practice and abstracted anonymized, retrospective data from the patients' medical records.
• The sample consisted of 45 physicians in the UK, 94 in Germany, and 45 in Spain, geographically dispersed across their respective countries. Patient selection criteria are listed in Table 1 . This is a preliminary analysis of a subset of patients with cleaned data.
Patient Demographics, Clinical Characteristics, and Follow-up
• Among 162 patients in the UK, 155 patients in Germany, and 159 patients in Spain, 64.8% to 78.6% were male and 89.5% to 98.7% were white (Table 2 ).
• In each country, between 82.7% and 94.3% of patients were not tested for PD-L1 expression at initial diagnosis (Table 1 ).
• The mean age at the index date was 59 to 60 years in each country (Table 1 ).
• The median duration of observable follow-up was 18.2 months in the UK, 17.5 months in Germany, and 19.3 months in Spain.
Concurrent Chemoradiation
• The mean (SD) duration of the index chemoradiation treatment was 2.4 (1.5) months in the UK, 2.1 (1.0) months in Germany, and 2.1 (1.1) months in Spain. The median number of cycles administered was 3 in the UK and Spain and 2 in Germany (Table 3 ).
-The index chemoradiation treatment included the first two cycles required for all patients to enter the study.
• At the start of the index chemoradiation treatment, 90.7%, 83.9%, and 88.1% of patients in the UK, Germany, and Spain, respectively, had a performance status of 0 or 1 (Table 3 ).
